CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

Roberto Petrioli; Antonella Licchetta; Giandomenico Roviello; Alessandra Pascucci; Edoardo Francini; Gianluca Bargagli; Raffaele Conca; Salvatora Tindara Miano; Giuseppe Marzocca; Guido Francini; Multidisciplinary Oncology Group on Gastrointestinal Tumors; Multidisciplinary Oncology Grp Gas

doi:10.3109/07357907.2011.629380

Back

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

Journal article

Peer reviewed

CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

Roberto Petrioli, Antonella Licchetta, Giandomenico Roviello, Alessandra Pascucci, Edoardo Francini, Gianluca Bargagli, Raffaele Conca, Salvatora Tindara Miano, Giuseppe Marzocca, Guido Francini, …

Cancer investigation, Vol.30(1), pp.65-71

01/01/2012

DOI: 10.3109/07357907.2011.629380

PMID: 22236191

View Online

Abstract

We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.

Details

Title: Subtitle: CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab
Creators: Roberto Petrioli - University of Siena
Antonella Licchetta - University of Siena
Giandomenico Roviello - University of Siena
Alessandra Pascucci - University of Siena
Edoardo Francini - University of Siena
Gianluca Bargagli - University of Siena
Raffaele Conca - University of Siena
Salvatora Tindara Miano - University of Siena
Giuseppe Marzocca - University of Siena
Guido Francini - University of Siena
Multidisciplinary Oncology Group on Gastrointestinal Tumors - University of Siena
Multidisciplinary Oncology Grp Gas
Resource Type: Journal article
Publication Details: Cancer investigation, Vol.30(1), pp.65-71
DOI: 10.3109/07357907.2011.629380
PMID: 22236191
ISSN: 0735-7907
eISSN: 1532-4192
Publisher: Informa Healthcare
Number of pages: 7
Language: English
Date published: 01/01/2012
Academic Unit: Internal Medicine
Record Identifier: 9985221247302771

Metrics

1 Record Views

37 Times Cited - Web of Science